Effector and regulatory B cells in Multiple Sclerosis.

[1]  S. Markovic‐Plese,et al.  Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS) , 2016, Journal of Neuroimmunology.

[2]  M. Rovaris,et al.  B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity , 2016, Scientific Reports.

[3]  R. Milo.  Therapeutic strategies targeting B-cells in multiple sclerosis. , 2016, Autoimmunity reviews.

[4]  R. Linker,et al.  Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy , 2016, Therapeutic advances in chronic disease.

[5]  Ariel Miller,et al.  Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis. , 2016, Journal of autoimmunity.

[6]  A. Goris,et al.  Immunologic profiles of multiple sclerosis treatments reveal shared early B cell alterations , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[7]  E. Bettelli,et al.  Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis , 2016, The Journal of Immunology.

[8]  R. Sobel,et al.  CNS accumulation of regulatory B cells is VLA-4-dependent , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[9]  Y. Mao-Draayer,et al.  Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[10]  J. Damoiseaux,et al.  Illuminating vitamin D effects on B cells – the multiple sclerosis perspective , 2016, Immunology.

[11]  Peter Nilsson,et al.  Anoctamin 2 identified as an autoimmune target in multiple sclerosis , 2016, Proceedings of the National Academy of Sciences.

[12]  P. Sørensen,et al.  The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects , 2016, Therapeutic advances in neurological disorders.

[13]  A. Bar-Or,et al.  Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy , 2015, Science Translational Medicine.

[14]  C. Kleinschnitz,et al.  The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients , 2015, Scientific Reports.

[15]  A. Vandenbark,et al.  IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice , 2015, Journal of Neuroimmunology.

[16]  K. Balashov,et al.  Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis , 2015, Multiple sclerosis.

[17]  H. Hartung,et al.  Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF , 2015, Multiple sclerosis.

[18]  L. Weiner,et al.  Effects of dimethyl fumarate on lymphocyte subsets. , 2015, Multiple sclerosis and related disorders.

[19]  Gregory F. Wu,et al.  Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance , 2015, Multiple sclerosis journal - experimental, translational and clinical.

[20]  Jiusheng Deng,et al.  Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients , 2015, Journal of multiple sclerosis.

[21]  E. Rosser,et al.  Regulatory B cells: origin, phenotype, and function. , 2015, Immunity.

[22]  T. Ben-Hur,et al.  Increased anti-KIR4.1 antibodies in multiple sclerosis: Could it be a marker of disease relapse? , 2015, Multiple sclerosis.

[23]  A. Vandenbark,et al.  Treatment with IL-10 producing B cells in combination with E2 ameliorates EAE severity and decreases CNS inflammation in B cell-deficient mice , 2015, Metabolic Brain Disease.

[24]  L. Steinman,et al.  IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity , 2015, The Journal of Immunology.

[25]  A. Bar-Or,et al.  Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[26]  S. Zamvil,et al.  Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[27]  C. Weaver,et al.  PD-L1hi B cells are critical regulators of humoral immunity , 2015, Nature Communications.

[28]  H. Wiendl,et al.  Annals of Clinical and Translational Neurology , 2014, Annals of clinical and translational neurology.

[29]  H. Wiendl,et al.  Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis , 2015, Multiple sclerosis.

[30]  K. Takeda,et al.  Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. , 2014, Immunity.

[31]  H. Kaku,et al.  A Novel Mechanism of B Cell–Mediated Immune Suppression through CD73 Expression and Adenosine Production , 2014, The Journal of Immunology.

[32]  D. Laplaud,et al.  Unaltered regulatory B-cell frequency and function in patients with multiple sclerosis. , 2014, Clinical immunology.

[33]  A. Bar-Or.  Teriflunomide (Aubagio®) for the treatment of multiple sclerosis , 2014, Experimental Neurology.

[34]  E. Rosser,et al.  Cellular targets of regulatory B cell-mediated suppression. , 2014, Molecular immunology.

[35]  M. Worm,et al.  Impaired T cell activation and cytokine production by calcitriol‐primed human B cells , 2014, Clinical and experimental immunology.

[36]  L. Davis,et al.  The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis. , 2014, JAMA neurology.

[37]  N. Hellings,et al.  Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study , 2014, PloS one.

[38]  Simon A. Jones,et al.  Regulatory B cells are induced by gut microbiota–driven interleukin-1β and interleukin-6 production , 2014, Nature Medicine.

[39]  M. Sirota,et al.  Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis , 2014, Science Translational Medicine.

[40]  M. Filippi,et al.  KIR4.1: another misleading expectation in multiple sclerosis? , 2014, The Lancet Neurology.

[41]  M. Romero,et al.  Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study , 2014, The Lancet Neurology.

[42]  W. Leonard,et al.  Autoimmunity: Regulatory B cells—IL-35 and IL-21 regulate the regulators , 2014, Nature Reviews Rheumatology.

[43]  J. Ochoa-Repáraz,et al.  Gut commensalism, cytokines, and central nervous system demyelination. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[44]  Ariel Miller,et al.  Gene Expression Profiling of the Response to Interferon Beta in Epstein-Barr-Transformed and Primary B Cells of Patients with Multiple Sclerosis , 2014, PloS one.

[45]  S. Baranzini,et al.  Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients , 2014, The Journal of Immunology.

[46]  C. Kleinschnitz,et al.  B1 cells are unaffected by immune modulatory treatment in remitting–relapsing multiple sclerosis patients , 2014, Journal of Neuroimmunology.

[47]  M. Rovaris,et al.  Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study , 2014, Multiple sclerosis.

[48]  Hyun-Dong Chang,et al.  Autocrine IL‐10 promotes human B‐cell differentiation into IgM‐ or IgG‐secreting plasmablasts , 2014, European journal of immunology.

[49]  S. Sánchez-Ramón,et al.  New regulatory CD19+CD25+ B-cell subset in clinically isolated syndrome and multiple sclerosis relapse. Changes after glucocorticoids , 2014, Journal of Neuroimmunology.

[50]  G. Giovannoni,et al.  The Refinement of Genetic Predictors of Multiple Sclerosis , 2014, PloS one.

[51]  S. Weigand,et al.  Pathologic heterogeneity persists in early active multiple sclerosis lesions , 2014, Annals of neurology.

[52]  Ellen Hilgenberg,et al.  B‐type suppression: A role played by “regulatory B cells” or “regulatory plasma cells”? , 2014, European journal of immunology.

[53]  C. Raoul,et al.  Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis , 2014, Multiple sclerosis.

[54]  A. Bar-Or,et al.  Teriflunomide and Its Mechanism of Action in Multiple Sclerosis , 2014, Drugs.

[55]  J. Tolson,et al.  The MIRROR Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and MRI Efficacy of Subcutaneous Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) (S23.006) , 2014 .

[56]  S. Kikuchi,et al.  Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations. , 2014, Clinical immunology.

[57]  M. Zygmunt,et al.  The Role of Pregnancy-Associated Hormones in the Development and Function of Regulatory B Cells , 2014, Front. Endocrinol..

[58]  Ariel Miller,et al.  Revised diagnostic criteria of multiple sclerosis. , 2014, Autoimmunity reviews.

[59]  Amit Bar-Or,et al.  IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases , 2014, Nature.

[60]  M. Filippi,et al.  Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis , 2014, Neurology.

[61]  T. Yamamura,et al.  Differential effects of fingolimod on B-cell populations in multiple sclerosis , 2014, Multiple sclerosis.

[62]  B. Hemmer,et al.  Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease , 2014, Neurology.

[63]  P. Tak,et al.  Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program , 2014, PloS one.

[64]  S. Hauser,et al.  In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses , 2014, Annals of neurology.

[65]  Li Li,et al.  The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro , 2013, Journal of Neuroimmunology.

[66]  A. Zenclussen,et al.  Cutting Edge: IL‐10‐Producing Regulatory B Cells in Early Human Pregnancy , 2013, American journal of reproductive immunology.

[67]  L. Weiner,et al.  Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod , 2013, Journal of Neuroimmunology.

[68]  P. Höllsberg,et al.  The B1-cell subpopulation is diminished in patients with relapsing–remitting multiple sclerosis , 2013, Journal of Neuroimmunology.

[69]  R. Maciuca,et al.  Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. , 2013, Arthritis and rheumatism.

[70]  E. Trinka,et al.  Glatiramer acetate attenuates the pro‐migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis , 2013, Clinical and experimental immunology.

[71]  A. Bar-Or,et al.  Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis , 2013, Neurology.

[72]  H. Wiendl,et al.  Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy , 2013, Multiple sclerosis.

[73]  J. Kira,et al.  Anti‐KIR4.1 antibodies in Japanese patients with idiopathic central nervous system demyelinating diseases , 2013 .

[74]  L. Serpero,et al.  Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients , 2013, Journal of Neuroimmune Pharmacology.

[75]  A. Vandenbark,et al.  PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE. , 2013, Journal of clinical & cellular immunology.

[76]  C. Akdis,et al.  IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. , 2013, The Journal of allergy and clinical immunology.

[77]  R. Hernández-Clares,et al.  Plasma exchange for steroid-refractory relapses in multiple sclerosis: an observational, MRI pilot study. , 2013, Clinical therapeutics.

[78]  T. Olsson,et al.  Changes to anti-JCV antibody levels in a Swedish national MS cohort , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[79]  W. Oertel,et al.  Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients , 2013, Multiple sclerosis.

[80]  D. Isenberg,et al.  CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation , 2013, Science Translational Medicine.

[81]  D. Cox,et al.  B cell exchange across the blood-brain barrier in multiple sclerosis. , 2012, The Journal of clinical investigation.

[82]  A. Vandenbark,et al.  Oestrogen treatment of experimental autoimmune encephalomyelitis requires 17β‐oestradiol‐receptor‐positive B cells that up‐regulate PD‐1 on CD4+ Foxp3+ regulatory T cells , 2012, Immunology.

[83]  Christian Confavreux,et al.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.

[84]  Jeffrey A. Cohen,et al.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.

[85]  M. Krumbholz,et al.  B cells and antibodies in multiple sclerosis pathogenesis and therapy , 2012, Nature Reviews Neurology.

[86]  Ariel Miller,et al.  Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis , 2012, Journal of Neuroimmunology.

[87]  P. Lampertico,et al.  IL-10–Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection , 2012, The Journal of Immunology.

[88]  D. Arnold,et al.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.

[89]  David H. Miller,et al.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.

[90]  P. Sørensen,et al.  Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis , 2012, Journal of Neuroinflammation.

[91]  T. Rothstein,et al.  Human “Orchestrator” CD11b+ B1 Cells Spontaneously Secrete Interleukin-10 and Regulate T-Cell Activity , 2012, Molecular medicine.

[92]  W. Leonard,et al.  Regulatory B Cells Control T Cell Autoimmunity Through IL-21-Dependent Cognate Interactions , 2012, Nature.

[93]  Bernhard Hemmer,et al.  Potassium channel KIR4.1 as an immune target in multiple sclerosis. , 2012, The New England journal of medicine.

[94]  P. Friend,et al.  B Cell Repopulation After Alemtuzumab Induction—Transient Increase in Transitional B Cells and Long-Term Dominance of Naïve B Cells , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[95]  E. Sabo,et al.  Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. , 2012, Autoimmunity reviews.

[96]  T. Holmøy,et al.  Intrathecal levels of vitamin D and IgG in multiple sclerosis , 2012, Acta neurologica Scandinavica.

[97]  D. Gray,et al.  B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells , 2012, The Journal of experimental medicine.

[98]  H. Sullivan,et al.  Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial , 2012, Neurology.

[99]  N. Salzman,et al.  A Novel IL-10–Independent Regulatory Role for B Cells in Suppressing Autoimmunity by Maintenance of Regulatory T Cells via GITR Ligand , 2012, The Journal of Immunology.

[100]  L. Davis,et al.  Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity , 2012, Autoimmunity.

[101]  Ludwig Kappos,et al.  Placebo-controlled trial of oral laquinimod for multiple sclerosis. , 2012, The New England journal of medicine.

[102]  R. Planas,et al.  Natalizumab treatment perturbs memory‐ and marginal zone‐like B‐cell homing in secondary lymphoid organs in multiple sclerosis , 2012, European journal of immunology.

[103]  G. Izquierdo,et al.  Immunological markers of optimal response to natalizumab in multiple sclerosis. , 2012, Archives of neurology.

[104]  E. Rosser,et al.  Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis , 2012, Arthritis Research & Therapy.

[105]  D. Piwnica-Worms,et al.  An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. , 2012, Human molecular genetics.

[106]  T. Rothstein,et al.  A small CD11b+ human B1 cell subpopulation stimulates T cells and is expanded in lupus , 2011, The Journal of experimental medicine.

[107]  M. Chiarini,et al.  Opposite effects of interferon-beta on new B and T cell release from production sites in multiple sclerosis patients , 2011, Journal of Neuroimmunology.

[108]  B. Scheithauer,et al.  Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.

[109]  I. Bekeredjian-Ding,et al.  B cells undergo unique compartmentalized redistribution in multiple sclerosis. , 2011, Journal of autoimmunity.

[110]  F. Barkhof,et al.  Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial , 2011, The Lancet.

[111]  P. Menheere,et al.  Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission , 2011, Journal of Neuroimmunology.

[112]  Moses Rodriguez,et al.  Evidence for the Role of B Cells and Immunoglobulins in the Pathogenesis of Multiple Sclerosis , 2011, Neurology research international.

[113]  R. Reynolds,et al.  Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.

[114]  A. Bar-Or,et al.  Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis , 2011, Neurology.

[115]  J. Damoiseaux,et al.  Effect of vitamin D3 supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis , 2011, Multiple sclerosis.

[116]  L. Joosten,et al.  The anti-CD20 antibody rituximab reduces the Th17 cell response. , 2011, Arthritis and rheumatism.

[117]  T. Vollmer,et al.  Recent insights into the mechanism of action of glatiramer acetate , 2011, Journal of Neuroimmunology.

[118]  R. Flavell,et al.  Mice Lacking Endogenous IL-10–Producing Regulatory B Cells Develop Exacerbated Disease and Present with an Increased Frequency of Th1/Th17 but a Decrease in Regulatory T Cells , 2011, The Journal of Immunology.

[119]  K. Bendtzen,et al.  Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production , 2011, Multiple sclerosis.

[120]  M. Krumbholz,et al.  Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab , 2011, Neurology.

[121]  S. Cepok,et al.  Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS , 2011, Neurology.

[122]  Yonggang Sha,et al.  B Cells as a Therapeutic Target for IFN-β in Relapsing–Remitting Multiple Sclerosis , 2011, The Journal of Immunology.

[123]  F. Breedveld,et al.  Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis , 2011, Annals of the rheumatic diseases.

[124]  E. Podack,et al.  The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model , 2011, Cancer Immunology, Immunotherapy.

[125]  E. S. St. Clair,et al.  Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. , 2011, Blood.

[126]  H. Jäck,et al.  B cell homeostasis and plasma cell homing controlled by Krüppel-like factor 2 , 2010, Proceedings of the National Academy of Sciences.

[127]  Volker Brinkmann,et al.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis , 2010, Nature Reviews Drug Discovery.

[128]  R. Reynolds,et al.  A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis , 2010, Annals of neurology.

[129]  Nitin J. Karandikar,et al.  Memory B cells from a subset of treatment‐naïve relapsing‐remitting multiple sclerosis patients elicit CD4+ T‐cell proliferation and IFN‐γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein , 2010, European journal of immunology.

[130]  T. Tedder,et al.  Regulatory B Cells (B10 Cells) and Regulatory T Cells Have Independent Roles in Controlling Experimental Autoimmune Encephalomyelitis Initiation and Late-Phase Immunopathogenesis , 2010, The Journal of Immunology.

[131]  H. Hartung,et al.  Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? , 2010, Archives of neurology.

[132]  H. Hartung,et al.  Atacicept: targeting B cells in multiple sclerosis , 2010, Therapeutic advances in neurological disorders.

[133]  T. Derfuss,et al.  Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury , 2010, Journal of Molecular Medicine.

[134]  N. Putzki,et al.  Effects of Natalizumab on Circulating B Cells, T Regulatory Cells and Natural Killer Cells , 2010, European Neurology.

[135]  S. Kikuchi,et al.  Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis , 2010, Journal of Neuroimmunology.

[136]  P. Calabresi,et al.  Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS? , 2010, Annals of neurology.

[137]  H. Offner,et al.  Progesterone treatment reduces disease severity and increases IL-10 in experimental autoimmune encephalomyelitis , 2010, Journal of Neuroimmunology.

[138]  T. Randall,et al.  Effector and regulatory B cells: modulators of CD4+ T cell immunity , 2010, Nature Reviews Immunology.

[139]  J. Ochoa-Repáraz,et al.  Induction of a regulatory B cell population in experimental allergic encephalomyelitis by alteration of the gut commensal microflora , 2010, Gut microbes.

[140]  Alok Sharma,et al.  Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis , 2010, Journal of Neuroimmunology.

[141]  F. Shi,et al.  B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis , 2010, Experimental Neurology.

[142]  D. Isenberg,et al.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. , 2010, Immunity.

[143]  U. Stervbo,et al.  Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll‐like receptors in immunity , 2010, Immunological reviews.

[144]  H. Sasaki,et al.  Memory and naïve B-cell subsets in patients with multiple sclerosis , 2009, Neuroscience Letters.

[145]  P. Calabresi,et al.  Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial , 2009, Annals of neurology.

[146]  L. Kappos,et al.  Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis1 , 2009, The Journal of Immunology.

[147]  P. Youinou,et al.  Regulatory B Cells in Autoimmune Diseases , 2009, Annals of the New York Academy of Sciences.

[148]  L. Boon,et al.  GITR Triggering Induces Expansion of Both Effector and Regulatory CD4+ T Cells In Vivo1 , 2009, The Journal of Immunology.

[149]  D. Hafler,et al.  Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid , 2009, Annals of neurology.

[150]  H. Lassmann,et al.  Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals , 2009, Proceedings of the National Academy of Sciences.

[151]  M. Krumbholz,et al.  Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis , 2008, Neurology.

[152]  M. Fujimoto,et al.  Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. , 2008, The Journal of clinical investigation.

[153]  J. Arthur,et al.  BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[154]  C. Baecher-Allan,et al.  Multiple Sclerosis and Regulatory T Cells , 2008, Journal of Clinical Immunology.

[155]  L. Qiao,et al.  Resting B cells expand a CD4+CD25+Foxp3+ Treg population via TGF‐β3 , 2008, European journal of immunology.

[156]  Andreas Radbruch,et al.  1,25‐dihydroxyvitamin D3 promotes IL‐10 production in human B cells , 2008, European journal of immunology.

[157]  M. Lindorfer,et al.  Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. , 2008, Current opinion in immunology.

[158]  J. Correale,et al.  Helminth infections associated with multiple sclerosis induce regulatory B cells , 2008, Annals of neurology.

[159]  R. Medzhitov.  Origin and physiological roles of inflammation , 2008, Nature.

[160]  H. von Büdingen,et al.  Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin‐specific antibodies , 2008, European journal of immunology.

[161]  R. Hohlfeld,et al.  Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis , 2008, Nature Medicine.

[162]  M. Krumbholz,et al.  Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. , 2008, Brain : a journal of neurology.

[163]  A. Bar-Or,et al.  B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators , 2008, Nature Reviews Immunology.

[164]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[165]  M. Fujimoto,et al.  A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. , 2008, Immunity.

[166]  D. Arnold,et al.  Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial , 2008, Annals of neurology.

[167]  C. Peschel,et al.  The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells , 2008, Leukemia.

[168]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[169]  L. Kappos,et al.  Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients , 2008, Journal of Neuroimmunology.

[170]  T. Olsson,et al.  Neurofascin as a novel target for autoantibody-mediated axonal injury , 2007, The Journal of experimental medicine.

[171]  P. Jensen,et al.  Cutting Edge: Primary B Lymphocytes Preferentially Expand Allogeneic FoxP3+ CD4 T Cells , 2007, The Journal of Immunology.

[172]  P. Lipsky,et al.  Modulatory Effects of 1,25-Dihydroxyvitamin D3 on Human B Cell Differentiation , 2007, The Journal of Immunology.

[173]  E. Waubant,et al.  Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling , 2007, Journal of Neuroimmunology.

[174]  T. Dörner,et al.  The Human Immunomodulatory CD25+ B Cell Population belongs to the Memory B Cell Pool , 2007, Scandinavian journal of immunology.

[175]  Gavin Giovannoni,et al.  Multiple sclerosis: the environment and causation , 2007, Current opinion in neurology.

[176]  M. Duddy,et al.  Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis , 2007, The Journal of Immunology.

[177]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response , 2007, Annals of the rheumatic diseases.

[178]  Yanping Tan,et al.  B Cell Regulation of CD4+CD25+ T Regulatory Cells and IL-10 Via B7 is Essential for Recovery From Experimental Autoimmune Encephalomyelitis1 , 2007, The Journal of Immunology.

[179]  J. Correale,et al.  Association between parasite infection and immune responses in multiple sclerosis , 2007, Annals of neurology.

[180]  S. Cepok,et al.  Immune surveillance in multiple sclerosis patients treated with natalizumab , 2006, Annals of neurology.

[181]  M. Fujimoto,et al.  Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. , 2006, The American journal of pathology.

[182]  J. Masjuán,et al.  Clinically isolated syndromes , 2006, Neurology.

[183]  Daniel Rodríguez‐Pinto.  B cells as antigen presenting cells. , 2005, Cellular immunology.

[184]  R. Sobel,et al.  Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions , 2005, Journal of Neuroimmunology.

[185]  W. Waldhäusl,et al.  Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. , 2005, Arthritis and rheumatism.

[186]  B. Weinshenker,et al.  Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange , 2005, The Lancet.

[187]  Cheng-ming Sun,et al.  Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. , 2005, Immunity.

[188]  Roland Martin,et al.  Immunology of multiple sclerosis. , 2005, Annual review of immunology.

[189]  J. Masjuán,et al.  Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. , 2005, The Journal of clinical investigation.

[190]  V. Roschke,et al.  Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus , 2004, Annals of the rheumatic diseases.

[191]  B. Serafini,et al.  Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.

[192]  C. D. Krause,et al.  Interleukin-10 and related cytokines and receptors. , 2004, Annual review of immunology.

[193]  H. Link,et al.  Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis , 2003, Journal of Neuroimmunology.

[194]  Vrajesh V. Parekh,et al.  B Cells Activated by Lipopolysaccharide, But Not By Anti-Ig and Anti-CD40 Antibody, Induce Anergy in CD8+ T Cells: Role of TGF-β11 , 2003, The Journal of Immunology.

[195]  David Gray,et al.  B cells regulate autoimmunity by provision of IL-10 , 2002, Nature Immunology.

[196]  Yuxin Lu,et al.  Lipopolysaccharide-Activated B Cells Down-Regulate Th1 Immunity and Prevent Autoimmune Diabetes in Nonobese Diabetic Mice1 , 2001, The Journal of Immunology.

[197]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[198]  D. Gilden,et al.  Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response , 2000, Neurology.

[199]  H. Reiber,et al.  The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis , 1998, Multiple sclerosis.

[200]  A. Reder,et al.  Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. , 1997, The Journal of clinical investigation.

[201]  Charles A. Janeway,et al.  Experimental Autoimmune Encephalomyelitis Induction in Genetically B Cell–deficient Mice , 1996, The Journal of experimental medicine.

[202]  H. Panitch,et al.  Interferon β-lb reduces Interferon γ-induced antigen-presenting capacity of human glial and B cells , 1995, Journal of Neuroimmunology.

[203]  Klaus Rajewsky,et al.  Impairment of T-cell-dependent B-cell responses and B-l cell development in CD19-deficient mice , 1995, Nature.

[204]  M. Sela,et al.  Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[205]  P. Dau.  Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease , 1990, Journal of Neuroimmunology.

[206]  D. Arnold,et al.  Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study , 2015 .

[207]  D. Arnold,et al.  A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. , 2014, Journal of neurology.

[208]  E. Mauch,et al.  Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients. , 2013, Atherosclerosis. Supplements.

[209]  A. Coles,et al.  B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis , 2009, Journal of Clinical Immunology.

[210]  E. Meinl,et al.  Therapeutic Advances in Neurological Disorders Glycoproteins as Targets of Autoantibodies in Cns Inflammation: Mog and More Therapeutic Advances in Neurological Disorders Review , 2022 .